NEW COMPOUNDS AND THEIR PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF INFLAMMATORY DISEASES Russian patent published in 2022 - IPC C07D471/04 C07D519/00 A61K31/437 A61K31/444 A61K31/4545 A61K31/496 A61K31/501 A61K31/506 A61K31/5377 A61K31/5386 A61P3/00 A61P19/00 A61P29/00 A61P35/00 A61P37/06 A61P37/08 

FIELD: pharmaceutical chemistry.

SUBSTANCE: group of inventions relates to pharmaceutical chemistry and includes a compound of the formula I or its pharmaceutically acceptable salt, as well as a pharmaceutical composition based on them. In the formula I, Cy is phenyl or 5-6-element heteroaryl containing one or two N atoms; L₁ is a simple bond, -O-, -C(=O)-, -S(O)₂-, -NR^6a-, -C(=O)NR^6b-, or -S(O)₂NR^6c-; R¹ is H; C_1-6 alkyl optionally substituted with one-four substitutes specified in the claims; C_3-7 cycloalkyl optionally substituted with one OH or C_1-4 alkoxy, octadeuteriomorpholine-4-yl, or 4-9-element monocyclic, or spirobicyclic, or bridged, or condensed bicyclic heterocycloalkyl containing one, or two, or three heteroatoms independently selected from N, S, and O; where heterocycloalkyl is optionally substituted with one-three independently selected R¹¹ groups; R¹¹ is independently: OH, CN, halogen, -NR^8aR^8b, C_3-7 cycloalkyl, C_1-4 alkyl optionally substituted with one-three substitutes independently selected from halogen, OH, C_1-4 alkoxy, or R^9aR^9b, C_1-4 alkoxy optionally substituted with one C_1-4 alkoxy, 4-6-element monocyclic heterocycloalkyl containing one or two heteroatoms independently selected from N and O, -C(=O)OC_1-4alkyl, or -NR^8cC(=O)OC_1-4 alkyl; R² is halogen or C_1-4 alkyl; n is equal to 0 or 1; L₂ is O or -NR⁴-; R³ is C_1-6 alkyl optionally substituted with one-four substitutes independently selected from halogen or C_3-7 cycloalkyl, phenyl substituted with one R^5a group and one or two independently selected R^5b groups, 6-element heteroaryl containing one or two N atoms, substituted with one R^5a group and one or two independently selected R^5b groups, 4-9-element monocyclic or spirobicyclic heterocycloalkyl containing one or two heteroatoms independently selected from N and O, optionally substituted with one, two, or three groups independently selected from R^5a and R^5b, or 4-10-element monocyclic or bridged cycloalkyl optionally substituted with one, two, or three groups independently selected from R^5a and R^5b; R⁴ is H, C_1-4 alkyl optionally substituted with one or two substitutes independently selected from OH or C_1-4 alkoxy, or C_3-7 cycloalkyl; R^5a is -CN, -SO₂-C_1-4 alkyl, or -CF₃; each R^5b is independently selected from halogen, C_1-4 alkyl, and C_3-7 cycloalkyl; each R^7a and R^7b is independently selected from H or C_1-4 alkyl optionally substituted with one -NR^10aR^10b; each R^6a, R^6b, R^6c, R^7c, R^7d, R^8a, R^8b, R^8c, R^9a, R^9b, R^10a, and R^10b is independently selected from H or C_1-4 alkyl.

EFFECT: compound of the formula I having inhibitory activity against JAK1, JAK2, JAK3, and TYK2.

14 cl, 1 dwg, 13 tbl, 1 ex